Editorial Policy

Last updated: April 27, 2026

GLP-1 Pets is the independent authority on veterinary GLP-1 weight loss drugs. This page explains our research process, source standards, and how we maintain honesty in a category where most search-volume content is either premature ("Ozempic for dogs is here!") or under-informed.

What We Cover

  • Active veterinary GLP-1 trials— Okava's OKV-119 (MEOW-1 trial in cats), Akston Biosciences' AKS-562c (Cornell trial in cats), and any future canine trials announced.
  • Regulatory pipeline — FDA actions on veterinary weight loss drugs, comparison to historical precedents (Slentrol, withdrawn 2013).
  • Companion animal obesity — body condition scoring, vet-formulated weight management food, portion control, and what works today while we wait.
  • Cross-context from the human GLP-1 space — when an FDA action, label change, or trial readout in human GLP-1 (semaglutide, tirzepatide, etc.) has implications for the pet pipeline, we cover it. We operate the sister site GLP-1 Picks so this cross-pollination is part of our normal workflow.

Source Standards

Every clinical or regulatory claim on this site links to one of:

  • Manufacturer press releases (Okava, Akston Biosciences, etc.)
  • Academic veterinary institutions (Cornell, University of Liverpool, etc.)
  • Peer-reviewed publications (JVIM, Veterinary Record, etc.)
  • FDA Center for Veterinary Medicine guidance documents
  • Association for Pet Obesity Prevention (APOP) clinical surveys
  • Veterinary trade press (dvm360, Veterinary Practice News, Smithsonian)

We do not source from anonymous social media, unverified consumer reports, or marketing copy from supplement brands.

What We Will Not Do

  • We will not claim FDA-approved pet GLP-1 exists before it does. As of publication, none does. We will update the day that changes.
  • We will not call non-GLP-1 supplements "natural Ozempic." That language is misleading and we refuse to participate in it.
  • We will not provide veterinary advice. Every page tells you to consult your vet. We are a research and information layer, not a treatment decision.
  • We will not promote off-label use of human GLP-1 in pets. Compounding and prescribing rules exist for safety reasons.

Editorial Independence

We accept no payment from drug manufacturers, vet pharma companies, telehealth platforms, or any party with an editorial interest in how we cover the pet GLP-1 pipeline. Affiliate relationships (Chewy, Amazon Associates) are limited to generic consumer products and never influence trial coverage. See our affiliate disclosure for details.

Corrections Policy

If you spot an inaccuracy — a wrong date, a misstated trial detail, an outdated regulatory status — email editor@glp1pets.com. We aim to investigate and correct within 48 hours, with a transparent "Updated" date on the affected page.

Freshness

Trial timeline pages (MEOW-1, Okava tracker, Akston Biosciences) are reviewed monthly and re-published as company announcements drop. Pillar guides (cat-obesity, dog-obesity) are reviewed quarterly. Every page shows the last review date.

Authorship

All content on GLP-1 Pets is authored or reviewed by Iacob Pastina, founder. We are seeking a named veterinary reviewer (DVM specializing in nutrition or internal medicine) for ongoing YMYL content review. If that's you, reach out.